

Biomarkers in Lung Cancer: Targeting the Right Patient With the Right Therapy

Light Bite, Lively Debate!

Monday, 22 October 2018

18:30 - 20:00

Hall A1 — Room 16

Messe Munich

Munich, Germany

Expert perspectives from:



Charles Rudin, MD, PhD










Raffaele Califano, MD



Maurice Pérol, MD

Agenda

- 18:30  Welcome and Introduction
- 18:35  Lung Cancer: The Rationale for Biomarkers
- 18:40  Which Therapy for Which Patient? Using Biomarkers to Drive Treatment Selection in NSCLC
- 19:15  Ask the Faculty: NSCLC
- 19:25  Targeting SCLC More Effectively: Can Biomarkers Improve Provision of Care?
- 19:45  Ask the Faculty: SCLC
- 19:55  Take-Home Messages

This programme is funded in part via an independent grant from AbbVie.

This independent medical education activity is organised by PeerVoice. PeerVoice activities are designed to fill the unmet needs of the medical community by reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. The preparation of PeerVoice activities is supported by written agreements that clearly stipulate and enforce the editorial independence of PeerVoice and the faculty presenters.